Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sunshine Biopharma Inc. (NASDAQ: SBFM) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into Sunshine Biopharma’s pharmaceutical and biotechnology operations, corporate governance, and financial reporting, complementing its public news releases about generics, biosimilars, and proprietary drug development.
Investors can review current reports on Form 8-K, where Sunshine Biopharma reports material events. Recent 8-K filings describe matters such as the dismissal of Bush & Associates CPA LLC as the company’s independent registered public accounting firm, the engagement of M&K CPAS, PLLC as its new auditor, and the outcomes of the annual meeting of stockholders. The December 2025 Form 8-K, for example, details the election of directors, ratification of M&K CPAS, PLLC for the 2025 audit year, and stockholder approval of an amendment to the 2023 Equity Incentive Plan to increase the number of shares authorized for issuance.
The platform also surfaces Sunshine Biopharma’s Definitive Proxy Statements on Schedule 14A, which outline proposals submitted to shareholders, board composition, corporate governance practices, executive compensation information, and procedures for the annual meeting. These filings help readers understand how the company is managed and how key decisions—such as equity incentive plan changes or auditor selection—are presented to and approved by shareholders.
On Stock Titan, Sunshine Biopharma’s 10-K annual reports, 10-Q quarterly reports, proxy statements, and 8-K current reports are supplemented with AI-powered summaries that explain complex sections in plain language. Users can quickly identify disclosures related to revenue sources, generic and biosimilar activities, research and development commitments, auditor changes, and equity incentive plans without reading every page. Real-time updates from EDGAR ensure that new filings, including any future Forms 4 reporting insider transactions, appear promptly, while AI-generated highlights point to sections that may be most relevant for analysis.
By using this filings page, investors, analysts, and researchers can efficiently review Sunshine Biopharma’s regulatory history, track governance and accounting developments, and connect formal SEC disclosures with the company’s broader strategy in generics, biosimilars, mRNA cancer therapies, and antiviral drug development.
Sunshine Biopharma Inc. reported a change in its independent auditor. Effective September 24, 2025, the company dismissed Bush & Associates CPA LLC as its independent registered public accounting firm and engaged M&K CPAS, PLLC as its new auditor. The board of directors and audit committee approved this decision by unanimous consent.
The company states that for the fiscal years ended December 31, 2023 and 2024, and through September 24, 2025, there were no disagreements with Bush & Associates on accounting principles, financial statement disclosure, or audit procedures, and no reportable events under SEC rules. Bush & Associates’ prior audit reports did not contain adverse opinions, disclaimers, or qualifications. Sunshine Biopharma has requested a letter from Bush & Associates to the SEC regarding these disclosures and plans to file it by amendment once received.